Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int

134
37. Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, et al. Tenofovir
disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine
and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic
Syndr 2008;47(1):74-8.
38. Lapadula G, Costarelli S, Quiros-Roldan E, Calabresi A, Izzo I, Carosi G, et al. Risk of
early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in
antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 2008;46(7):1127-9.
39. Towner W, Kerrigan HL, LaRivière M, et al. eds. Efficacy of a once-daily regimen of
nevirapine(NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naive HIV-infected
patients: a pilot study. Seventh International Congress on Drug Therapy in HIV Infection;
2004.
40. Vicente Soriano SK, Horacio Migrone et al, editors. Prospective randomised comparison
of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in
treatment-naive HIV-1 infected patients: ARTEN Study, week 48 results. 5th IAS
Conference on HIV Pathogenesis, Treatment and Prevention; July 19−22 2009; Cape
Town, South Africa.
41. Alexandra Calmy AN, J Lange, M Battegay, F de Wolf, P Reiss, B Hirschel, F Wit, and for
the Swiss HIV Cohort Study and the Netherlands ATHENA Observational Cohort, eds.
Nevirapine administered once daily is as efficient as a twice-daily dosing. A collaborative
cohort study. 15th Conference on Retroviruses and Opportunistic Infecions; 2009; Boston.
42. Havlir DV, Koelsch KK, Strain MC, Margot N, Lu B, Ignacio CC, et al. Predictors of residual
viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus
either tenofovir or stavudine. J Infect Dis 2005;191(7):1164-8.
43. Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S, et al. Stability of
antiretroviral regimens in patients with viral suppression. AIDS 2008;22(9):1039-46.
44. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, et al. Increased
regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.
AIDS 2008;22(15):1951-60.
45. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, et al. Relationship
between antiretrovirals used as part of a cART regimen and CD4 cell count increases in
patients with suppressed viremia. AIDS 2006;20(8):1141-50.
46. Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, et al. CD4+ T-cell
count increase in HIV-1-infected patients with suppressed viral load within 1 year after
start of antiretroviral therapy. Antivir Ther 2007;12(6):889-97.
47. Sanchez-de la Rosa R, Herrera L, Moreno S. Cost-effectiveness analysis of emtricitabine/
tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviralnaive,
HIV-1-infected patients. Clin Ther 2008;30(2):372-81.
TraTamienTo anTirreTroviral de la infección por el viH en adulTos y adolescenTes
recomendaciones para un enfoque de salud pública